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p62/Sequestosome 1 is a scaffold protein involved in the reg-
ulation of autophagy, trafficking of proteins to the proteasome,
and activation of NF-B. p62 encodes an N-terminal PB1
domain in addition to the ZZ domain, TRAF6-binding domain,
LC3 interaction region, and ubiquitin-associated domain, each
critical for the physiological function of p62. PB1 domains have
a-grasp topologywhere the front endof onePB1domainbinds
the back end of a second PB1 domain. The p62 PB1 domain
homodimerizes as well as heterodimerizes with other PB1
domains. The front end of the PB1 domain in p62 binds the PB1
domain of atypical protein kinases C, the MAPK kinase, MEK5,
and theNBR1 protein. Other than its role in homodimerization,
the rear end acidic cluster region of the p62 PB1 domain had no
previous defined binding partners. Herein, we demonstrate that
the rear end acidic cluster region of the p62 PB1 domain binds
the front end basic region of the MAPK kinase kinase, MEKK3.
p62 and MEKK3 co-localize in speckles or aggregates that are
centers for organizing TRAF6-regulated NF-B signaling and
the assembly of polyubiquinated proteins sorting to sequesto-
somes and proteasomes. The p62-MEKK3 complex binds
TRAF6, which regulates the ubiquitination of the IKK complex
and NF-B activation. p62 is required for the association of
MEKK3 with TRAF6 and short hairpin RNA knockdown of p62
inhibits IL-1 and MEKK3 activation of NF-B. The rear end
acidic cluster of the p62 PB1 domain is used to organize cytoso-
lic aggregates or speckles-associated TRAF6-p62-MEKK3 com-
plex for control of NF-B activation.
p62/Sequestosome 1 is a scaffold protein of 62 kDa encoding
multiple binding domains for proteins involved in signaling,
ubiquitination, and autophagy. The N-terminal PB1 (Phox/
Bem 1p) domain has been shown to bind the PB1 domains of
atypical PKCs3 (1), MEK5 (2), and NBR1 (neighbor of BRCA1
gene 1) (2). Additional domains encoded in p62 include the
ZZ-type zinc finger domain that binds RIP1 (receptor-interact-
ing protein-1), a TRAF6-binding domain, an LC3 interaction
region (3), and a ubiquitin-associated domain (4). p62 is found
in cytosolic speckles and aggregates referred to as sequesto-
somes and is thought to link the autophagy machinery to poly-
ubiquitinated proteins (3). p62 polymerizes via its PB1 domain
and binds ubiquitinated proteins via its ubiquitin-associated
domain and, via its LC3 interaction region, binds the LC3 pro-
tein, which is a member of the autophagosomal machinery (5).
p62 also regulatesNF-B activation by its interactionwith RIP1
(6) and TRAF6 (7). The p62-TRAF6 complex appears to regu-
late both phosphorylation (8) and ubiquitination (9, 10) of the
IKK complex. Deletion of p62 has been shown to inhibit RANK
ligand-stimulated NF-B activity, resulting in impaired oste-
oclastogenesis associated with Paget disease of bone (11). p62
also appears important for NF-B regulation in response to
neurotrophic factors (12) and inflammatory cytokines, includ-
ing IL-1 (7) and tumor necrosis factor (6). p62 knock-outmice
are insulin-resistant and obese, apparently due to a loss of
ERK1/2 regulation in adipogenesis (13). Most recently, p62 has
been shown to promote tumorigenesis in autophagy-deficient
tumor cells by altering NF-B regulation (14).
The PB1 domain of p62 is critical for many of its defined
cellular and physiological functions. PB1 domains regulate pro-
tein interactions primarily by forming heterodimers using a 
grasp topology that uses a “front-to-back” arrangement of the
two PB1 domains (4). This ubiquitin-like grasp domain uses
clusters of basic amino acids in the front of one PB1 domain to
bind acidic amino acids in the back of a second PB1 domain.
“A-type” PB1 domains have conserved acidic residues, and
“B-type” PB1 domains have a conserved lysine or arginine in the
basic region. The p62 PB1 domain has both a basic front end
and acidic rear end (A-B type PB1 domains) and can therefore
homodimerize as well as heterodimerize (2). It is the unique
homodimerization of the p62 PB1 domain that confers its abil-
ity to form polymers that are a component of aggregates of
ubiquitinated proteins in the autophagy pathway. The het-
erodimerization property of the p62 PB1 domain allows p62
binding of other PB1 domain proteins, such as atypical PKCs,
MEK5, and NBR1.
We have previously characterized the role of PB1 domains of
the MAPK kinase kinases, MEKK2 and MEKK3 (15). MEKK2
and MEKK3 PB1 domains bind the PB1 domain of the MAPK
kinase, MEK5, which phosphorylates and activates the MAPK,
ERK5 (16). Although MEKK2 and MEKK3 PB1 domains are
highly homologous, they do have differential regulatory prop-
erties.We have shown that theMEKK2 PB1 domain has a non-
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canonical function in bindingMKK7, aMAPK kinase that acti-
vates JNK (17). A substantial literature exists suggesting that
MEKK3, but notMEKK2, regulatesNF-B (18–25). Themech-
anism for how MEKK3 but not MEKK2 could selectively acti-
vateNF-B is not defined.Herein, we demonstrate that the PB1
domains ofMEKK3 and p62 heterodimerize using the C-termi-
nal acidic cluster of p62 and the N-terminal basic region of
MEKK3. The PB1 domain-dependent MEKK3-p62 complex
localizes to cytosolic p62 speckles/aggregates and mediates
MEKK3 activation of NF-B.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—HEK293 and COS7 cells were
maintained in Dulbecco’s modified Eagle’s medium (Invitro-
gen) with 10% heat-inactivated fetal calf serum, 100 units/ml
penicillin, and 100 g/ml streptomycin at 37 °C with 7% CO2.
Recombinant human IL-1was obtained fromPeproTech. The
mAb (12CA5) against the hemagglutinin (HA) epitope (for
immunoprecipitation and staining) was from Roche Applied
Science. A mouse mAb for MEKK2 was generated against
recombinant MEKK2. Anti-MEKK3 Ab was purchased from
Epitomics. Anti-FLAG (M5), -ERK5, and -p62 (for staining)
Abs were from Sigma. ThemousemAbs forMEK5 and p62 (for
blotting and staining) were purchased from BD Biosciences.
Anti-phospho-ERK5 antibody was from Cell Signaling. Poly-
clonal anti-TRAF6 and -HA Abs (for blotting and staining)
were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 555 goat anti-
mouse Abs were obtained from Invitrogen. Firefly 3 NF-B
luciferase reporter gene was generously provided by Dr. A. S.
Baldwin (University of North Carolina). MEF2C luciferase
reporter gene (3 MEF2-luc) was constructed with a thymi-
dine kinase promoter with three copies of a high affinity MEF2
binding site from the desmin gene (26). pRL-TK Renilla lucif-
erase reporter gene was obtained from Promega.
DNA Constructs—GST fusions were constructed in pGEX
5X-1, using the cDNA fragments amplified by PCR. His-PB1
domain proteins with a hexahistidine epitope at theN terminus
of each proteinwere engineered by PCR and cloned into pRSET
(Invitrogen). The indicated residueswere replaced byAla, using
PCR-based mutagenesis, and coding amino acids are described
in the figure legends. For lentiviral infections, shRNA for
human p62 (TRCN0000007233, -34, -35, -36, and -37) or con-
trol shRNAwas in pLKO.1 vector (Open Biosystems). For tran-
sient expression in HEK293 cells, HA-MEKK2, HA-MEKK3,
FLAG-MEK5, and FLAG-p62 were inserted into the pCMV5
expression vector. HA-p62, provided by Dr. J. Moscat (Uni-
versity of Cincinnati), FLAG-TRAF6, andXpress-ERK5were in
pcDNA3. HA- and FLAG-p62 PB1 domain (aa 1–107) were
inserted in pCMV5. HA-MEKK2-MEKK3 chimeric molecules
were generated as a combination of eitherMEKK2 PB1 domain
(aa 1–122) and MEKK3 (aa 124–626) (MEKK2 PB1-MEKK3)
or MEKK3 PB1 domain (aa 1–123) and MEKK2 (aa 123–619)
(MEKK3 PB1-MEKK2).
Pull-down Assays with GST Fusion Proteins—Different GST
fusion proteins were coupled to glutathione beads. Total cell
lysates were prepared from HEK293 cells transiently trans-
fected with DNA constructs using a solubilizing buffer. GST
fusion proteins on glutathione beads were incubated with 1 mg
ofHEK293 cell lysate at 4 °C for 2 h. The beadswerewashed five
times with solubilizing buffer, and the protein complex isolated
on the beadswas subjected to SDS-PAGE and immunoblotting.
Surface Plasmon Resonance Assay—GST fusion proteins
were purified using glutathione-Sepharose beads. Various His6
fusion proteins were purified by nickel-His interaction. Analy-
sis was conducted using a Biacore 3000 instrument, and data
were evaluated with BIAevaluation 3.2 (Biacore). Running
buffer contained 10 mM Hepes, pH 7.5, 150 mM NaCl, 3 mM
EDTA, 0.0005% Nonidet P-40. Anti-GST Ab was immobilized
on a carboxymethyldextran surface on a CM5 sensorchip (GE
Healthcare). Ligands, GST-PB1 domain fusion or GST protein,
FIGURE 1. A novel PB1 domain interaction between p62 and MEKK3.
A, pull-down assay of HA-tagged p62 PB1 domain using GST-MEKK3. HA-
tagged p62 PB1 domain (D69A/E70A and K7A) or empty vector was
expressed in HEK293 cells. These cell lysates were provided for a pull-down
assay with either GST-MEKK3 or -p40phox PB1 domain as a negative control.
Binding was detected by anti-HA Ab blotting. The bottom panel shows the
expression of each HA-tagged protein. B, p62 binds to both MEKK3 and MEK5
but in an opposite manner. A pull-down assay was conducted with MEKK2
(wild type), MEKK3 (wild type or K48A mutant), and MEK5 (wild type, D64A/
E65A, or K22A mutant) GST-PB1 domains from HA-p62 PB1 domain (D69A/
E70A or K7A)-expressing HEK293 cells. The detection was by the same
method as stated in A. The bottom panel is an anti-HA Ab blot to show equal
input in the pull-down assay. WT, wild type; 69.70DE-AA, D69A/E70A; 7K-A,
K7A; 64.5DE-AA, D64A/E65A; 22K-A, K22A; 48K-A, K48A.
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captured on an anti-GST Ab-coupled sensorchip were used to
see ligand-analyte interaction. After use, antibody-coated sen-
sorchip surfaces were regenerated with 40 l of 10 mM glycine,
pH 1.9, and used for another GST-ligand coupling. Upon cou-
pling a ligand, eachGST fusion proteinwas accumulated until a
surface density of 800 response units was achieved. His-PB1
FIGURE 2. Broad analyses of mammalian PB1 domain interactions using a surface plasmon resonance biosensor. An overlay of the sensorgrams was
prepared using a ligand, GST-PB1 domain immobilized on the sensor surface coated with anti-GST Ab, and analytes, various His-PB1 domains, in flow. Each
sensorgram is shown after subtraction of nonspecific binding to a GST only-coated sensorchip. Five M His-PB1 domain analytes in flow was run over each
GST-PB1 domain-coated sensor surface. Magnitude of the binding (y axis) is shown as response units (RU). The x axis is run time in seconds, with analyte
injection starting at time 0 and ending at time 600 s. WT, wild type; 69.70DE-AA, D69A/E70A; 7K-A, K7A; 64.65DE-AA, D64A/E65A; 22K-A, K22A; 47K-A, K47A; 48K-A, K48A.
TABLE 1
Summary of PB1 domain interactions
Plus andminus signs indicatepositive andnegativebindingbasedon the surfaceplasmonresonance spectroscopy results of Fig. 2, respectively.TheKd value for specific PB1domain
interactions was calculated according to dose-response measurements with increasing concentrations (5 nM to 5 M) of His-PB1 domains passed over GST-PB1 domain immo-
bilized on the sensor surface coatedwith anti-GSTAb, as described under “Experimental Procedures” and the legend to Fig. 2. Datawere analyzed using global fitting of association
(kon) and dissociation (koff) rates using BIAevaluation software except p40phox-p67phox interaction. The affinity in p40phox-p67phox binding was calculated based on the equilibrium
binding measurements at each different concentration of analyte. The Kd values (nM, except M in p40phox-p67phox) are shown in parentheses. NT, not tested.
GST-K2WT GST-K3WT GST-K5WT GST-p40phox GST-p62D69A/E70A p62 K7A
His-K2 WT      
His-K3 WT      
His-K5 WT  (25.4 nM)  (24.8 nM)    
His-p40phox      
His-p67phox     (3.47 M)  
His-p62 D69A/E70A    (116 nM)   
p62 K7A  (89.1 nM)  (19.3 nM)    (5.91 nM) 
K2 K47A NT NT  NT NT 
K3 K48A NT NT  NT NT 
K5 D64A/E65A   NT NT  
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domain proteins were injected at a
flow rate of 20 l/min, and associa-
tion and dissociation phases were
recorded for 10 and 5 min, respec-
tively. Nonspecific binding mea-
sured by using a flow cell of GST
alone was subtracted from the value




three times with ice-cold phos-
phate-buffered saline (PBS) and
lysed with solubilizing buffer (1%
Nonidet P-40, 10 mM Tris, pH 7.5,
150mMNaCl, 0.4mMEDTA, 10mM
NaF, 2 mM Na3VO4, 1 g/ml leu-
peptin, 1 g/ml aprotinin, 1 g/ml
1-antitrypsin, and 1 mM phe-
nylmethylsulfonyl fluoride), and
cleared supernatants were retained
for further processing. Lysates were
subjected to immunoblotting or
immunoprecipitation with anti-
HA, -MEKK2, or -MEKK3 Ab. For
immunoprecipitation, immune com-
plexes were collected with protein
G- or A-Sepharose beads, separated
by SDS-PAGE, and transferred to
a nitrocellulose membrane. After
blocking, membranes were blotted
with the indicated Abs and visual-
ized using the Supersignal West
Pico detection system (Pierce). As
to protein phosphatase treatment,
immunoprecipitate was incubated
with -protein phosphatase (New
England Biolabs) in a 50-l reaction
buffer supplied by themanufacturer
for 50 min at 30 °C. For the in vitro
kinase assay, immunoprecipitate
was incubated with a 50-l kinase
buffer (0.05% Nonidet P-40, 20 mM
HEPES, pH7.5, 50mMNaCl, 2.5mM
MgCl2, 20 mM -glycerophosphate,
0.1 mM Na3VO4, 2 mM dithiothrei-
tol, and 0.1 mM ATP) for 50 min at
30 °C. After the reaction, immuno-
precipitates were washed with solu-
bilizing buffer three times and pro-
vided for further processing.
Immunostaining and Co-local-
ization Analysis—Genes of interest
were introduced into COS7 cells on
22-mm square glass coverslips in a
6-well plate using Lipofectamine
and Plus reagent (Invitrogen). After
24 h, the cells on coverslips were
p62 and MEKK3 PB1 Domain Binding
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fixed for 10 min with 4% (w/v) paraformaldehyde in PBS at
room temperature. Permeabilizationwas conducted using 0.2%
Triton X-100 in PBS for 10 min at room temperature. Nonspe-
cific binding was blocked by incubation of coverslips for 1 h in
10%goat serum inPBS. The coverslipswere incubatedwithAbs
(either polyclonal anti-HA Ab and anti-FLAG M5 mAb, poly-
clonal anti-p62 and anti-HA (12CA5) mAb, or polyclonal anti-
TRAF6 Ab and anti-p62 or -HA mAb for 1 h at room temper-
ature) and washed with PBS three times for 5 min each time.
Bound primary Abs were visualized by incubation with Alexa
Fluor 488 goat anti-rabbit Ab and Alexa Fluor 555 goat anti-
mouse Ab for 1 h at room temperature, washed, and mounted
on glass slides. Imaging was performed using a Zeiss Axiovert
200 M inverted microscope with a 125-watt xenon arc lamp
(Sutter Instrument Company, Novato, CA), digital CCD cam-
era (CoolSNAP HQ, Roper Scientific, Tucson, AZ), and Slide-
book 5.0 software (Intelligent Imaging Innovations, Denver,
CO). An objective (63 oil 1.25 numerical aperture, Plan-
Neofluar, Zeiss) was coupled with immersion oil to the bottom
face of glass coverslips. Using fluorescein isothiocyanate (for
Alexa Fluor 488) and Cy3 (for Alexa Fluor 555) filter sets
(Chroma), the images were obtained at 50- and 10-ms exposure
with 2 2 binning, respectively. For section analyses, the back-
ground-subtracted images were transferred to the ImageJ pro-
gram, and green and red fluorescence intensities in each section
were numerically processed. The relative intensity was calcu-
lated as a fraction of themaximumnumber in each section, and
the graphs were created using the GraphPad Prism 5 program
(La Jolla, CA).
p62 Knockdown in Cells Using Lentiviral shRNAs—HEK293
cells were used as packaging cells for the lentiviral gene transfer
system. pLKO.1 vectors and packaging mix (Open Biosystems)
were transfected into HEK293 cells. Two days after transfec-
tion, the supernatants were collected and diluted with the same
volume of fresh completeDulbecco’smodified Eagle’smedium,
and Polybrene was added to the infection medium at 8 g/ml.
The infection mixtures were added to cell cultures seeded on a
6-well plate, incubated overnight, and then replaced with fresh
complete Dulbecco’s modified Eagle’s medium containing 8
g/ml puromycin. The puromycin-resistant cells were isolated
and propagated for use in the experiments.
Luciferase Assay—Cells in a 12-well plate were transfected
with 140 ng of firefly luciferase reporter construct harboring
three tandem NF-B or MEF2 binding sites and 14 ng of
pRL-TK Renilla luciferase construct (Promega) along with the
indicated amount of plasmid using Lipofectamine and Plus re-
agent. The cells were cultured for 24 h, starved of serum for 8 h,
harvested in passive lysis buffer, and analyzed using the Dual-
Luciferase reporter assay system (Promega). NF-B or MEF2C
luciferase activity was normalized to Renilla luciferase activity
and presented as relative luciferase activity. The data are shown
as an average of relative luciferase activity in triplicate with an
error bar of S.D.
RESULTS
MEKK3 and p62 PB1 Domains Heterodimerize—In an
attempt to define PB1 domain interactions, we have expressed
different PB1 domains as eitherGST fusions orHA-tagged pro-
teins. Because p62 PB1 domains homodimerize as well as het-
erodimerize, we expressed mutant PB1 domains having the
basic region mutation K7A or the acidic cluster mutation
D69A/E70A.TheK7AandD69A/E70Ap62PB1domains fail to
homodimerize but are able to heterodimerize with specific
B-type and A-type PB1 domains, respectively. Our screen with
recombinant PB1 domains identified the ability of the p62 PB1
domain to bind theMEKK3 PB1 domain (Fig. 1A). TheMEKK3
PB1 domain bound the K7A but not the D69A/E70A PB1
domain of p62. The p40phox PB1 domain, which binds the
p67phox PB1 domain in Fig. 2 and Ref. 27, does not bind the p62
PB1 domain, demonstrating the specificity of PB1 domain
interactions.
The PB1 domains of MEKK2 andMEKK3 are highly homol-
ogous, and both use the front end basic region of their PB1
domains to bind the MEK5 PB1 domain (15). Fig. 1B shows
pull-down assays using GST-PB1 domains from MEKK2,
MEKK3, and MEK5. The MEKK3 PB1 domain but not the
MEKK2 PB1 domain binds the K7A p62 PB1 domain. In con-
trast to the MEKK3 PB1 domain, the MEK5 PB1 domain binds
D69A/E70A p62 PB1 domain. Thus, the MEKK3 PB1 domain
binds the C-terminal acidic cluster, and theMEK5 PB1 domain
binds the N-terminal basic region of the p62 PB1 domain. This
shows that the PB1 domains ofMEKK3 andMEK5use different
regions of the p62 PB1 domain for binding, allowing potentially
different signaling modules to be organized by p62.
Surface plasmon resonance spectroscopy was used to meas-
ure the interactions of PB1 domains for MEKK2, MEKK3,
MEK5, p62, p40phox, and p67phox. Fig. 2 characterizes the inter-
actions of the different PB1 domains with the results showing
that (i) the basic regions of MEKK2 and MEKK3 PB1 domains
bind the acidic cluster of theMEK5 PB1 domain; (ii) theMEK5
acidic cluster binds the basic region of the p62 PB1 domain; (iii)
the basic region of MEKK3 andMEKK2 PB1 domains bind the
acidic cluster of the p62 PB1 domain; (iv) the p40phox PB1
domain bound only the p67phox PB1 domain, consistent with
the specificity of PB1 domain interactions.
The finding that theMEKK2 PB1 domain could bind the p62
PB1 domain using surface plasmon resonance contrasts with
the GST-PB1 domain pull-downs in Fig. 1B, where theMEKK2
FIGURE 3. Binding specificity of full-length protein to PB1 domain. A, pull-down assay of full-length HA-p62 (D69A/E70A-AA, K7A), HA-MEKK2, and
FLAG-MEK5 using GST-MEKK3 and -MEK5 PB1 domain. The top two panels show the binding specificity of each protein to either MEKK3 or MEK5 PB1 domain.
The bottom two panels show the expression of proteins. B, pull-down assay in a reverse way as A. Expressed full-length MEKK3 (wild type, K48A) and MEK5 (wild
type, D64A/E65A) proteins were precipitated using GST-p62 (D69A/E70A, K7A) or -p40phox PB1 domain. C, endogenous p62 binds to MEKK3, depending on PB1
domain interaction. HA-MEKK2, -MEKK3 (wild type or K48A), or empty vector was expressed in HEK293 cells. HA proteins were immunoprecipitated with
anti-HA Ab. Co-immunoprecipitates were analyzed by anti-p62, -MEK5, and -HA Abs sequentially (left panel). The right panel shows the expression of endog-
enous p62 and MEK5 in the cells. D, MEKK3 PB1 domain confers the p62 binding capability on MEKK2. HA immunoprecipitates from HA-MEKK2 or -MEKK3 PB1
domain fused to PB1 MEKK2 (MEKK3 PB1 (wild type or K48A)-MEKK2 chimera)-expressing cells were analyzed with anti-p62, -MEK5, and -HA Abs. E, HA-MEKK3
or -MEKK2 PB1 (wild type or K47A)-MEKK3 chimera was expressed in HEK293 cells. Anti-HA Ab immunoprecipitates were analyzed with anti-p62, -MEK5, and
-HA Abs. I.P., immunoprecipitation; WT, wild type; 69.70DE-AA, D69A/E70A; 7K-A, K7A; 48K-A, K48A; 47K-A, K47A.
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PB1 domain did not bind the p62 PB1 domain as detected by
immunoblotting in pull-down assays. Dose-response experi-
ments were conducted with increasing concentrations of His-
K7A p62 PB1 domain and immobilized GST-MEKK3 or
MEKK2PB1domain. ThePB1domains ofMEKK2 andMEKK3
have similar affinities (25 nM) for the MEK5 PB1 domain
(Table 1). In contrast, the MEKK3 PB1 domain has a 4.6-fold
higher affinity for the K7A p62 PB1 domain than the MEKK2
PB1 domain (19 nM for MEKK3 versus 89 nM for MEKK2
PB1 domains). Reciprocal experiments where the K7A p62 PB1
domain was immobilized on the sensorchip and theMEKK3 or
MEKK2 PB1 domains were used in the flow solution gave sim-
ilar results (data not shown). This difference in binding affinity
most likely accounts for the differential results that are
observed in pull-down assays and clearly shows a selectivity of
p62 PB1 domain binding to MEKK3 versus MEKK2 PB1
domains.
Specificity of MEKK3-p62 PB1 Domain Interaction—The
cumulative findings in Fig. 3 show that the interaction of full-
length proteins for MEKK3 and p62 is dependent on their
respective PB1 domains. Fig. 3A shows that the MEK5 and
MEKK3 PB1 domains bind full-length D69A/E70A and K7A
p62, respectively, indicating that the PB1 domains dictate high
affinity interaction. Fig. 3B further shows that the basic cluster
residue Lys48 in theMEKK3PB1 domain is required for binding
the p62 PB1 domain. In contrast, theMEK5 PB1 domain acidic
cluster (64DE65) is required for binding the p62 PB1 domain.
Endogenous p62 andMEK5 both bindHA-MEKK3 (Fig. 3C).
In contrast, HA-MEKK2 binding to endogenous p62 is not
detected using immunoprecipitation assays. However, similar
to MEKK3, MEKK2 binds MEK5 by immunoprecipitation,
consistentwith p62 selectively bindingMEKK3,whereasMEK5
binds bothMEKK2 andMEKK3.Mutation of K48A in the basic
cluster of the MEKK3 PB1 domain inhibits the binding of
MEKK3 to endogenous p62 and MEK5 proteins, confirming
the role of the basic region in the MEKK3 PB1 domain and
front-to-back binding orientation of the MEKK3 PB1 domain
with both p62 and MEK5.
Chimeras were synthesized where the MEKK2 and MEKK3
PB1 domains were swapped between the two proteins (Fig. 3,D
and E). Endogenous p62 was co-immunoprecipitated with the
chimera having a MEKK3 PB1 domain fused with the MEKK2
kinase domain. In contrast, the chimera having theMEKK2PB1
domain and MEKK3 kinase domain did not bind p62. As pre-
dicted, endogenousMEK5was able to bind both chimeras. The
cumulative results are the first demonstration of a PB1 domain
interaction with the C-terminal acidic cluster region of p62
other than p62-p62 PB1 domain homodimerization. MEK5,
NBR1, and the atypical PKCs bind the N-terminal basic region
of p62 (2, 28, 29).
p62 Aggregates Bind MEKK3—p62 readily forms aggregates
or speckles in the cytoplasm by oligomerizationmediated by its
PB1 domain (1, 3). Multiple proteins are recruited to the p62
aggregates, including TRAF6, atypical PKCs, NBR1, caspase-8,
NF-B, and polyubiquitinated proteins (30). Fig. 4A shows that
expressed wild type p62 forms characteristic aggregates in the
cytoplasm. In contrast, K7A p62 having a disrupted PB1-PB1
domain homodimerization fails to form aggregates because it is
unable to form p62 oligomers. Expression of MEKK3 results in
a diffuse cytoplasmic staining with an absence of MEKK3
aggregates. Fig. 4B shows that co-expression of MEKK3 and
wild type p62 results in the co-localization of MEKK3 in p62
aggregates. For quantitation of co-localization (Fig. 4C), inten-
sity profiles for eachmarkerwere generated by placing identical
linear regions of interest upon both images for each image pair.
The intensity values for each pixel were extracted along each
line, normalized by setting the peak values to 100%, and then
graphed against distance. These traces demonstrate the degree
of correlation between the spatial distributions of the two pro-
teins for each condition. The analysis shows that a component
of expressed wild typeMEKK3 and wild type p62 co-localize in
aggregates, as shown in the coordinate peaks of intensity in the
upper left panel of Fig. 4C. The lower left panel of Fig. 4C also
shows thatK7Ap62,which is unable to formp62 aggregates but
still binds MEKK3, is co-localized with MEKK3 in the cyto-
plasm.Mutation ofMEKK3 or p62 PB1 domains, such that they
are unable to heterodimerize, results in a diffuse localization of
MEKK3 and loss of co-localization with p62.
Fig. 5 shows the comparative analysis of endogenous p62
co-localization with MEKK3 and MEKK2. Images and quanti-
tation of intensity profiles show thatMEKK3 co-localizes in p62
aggregates similar to that shown in Fig. 4. In contrast,MEKK2 is
diffusely localized in the cytoplasm and is not found to be con-
centrated in p62 aggregates. These results confirm the pull-
down and immunoprecipitation assays showing that MEKK3
but not MEKK2 binds p62 and that MEKK3 is found in p62
cytoplasmic aggregates.
p62 Is Required forMEKK3Association in TRAF6Complexes—
p62 is well characterized to bind TRAF6 (7, 12). Fig. 6A shows
by coimmunoprecipitation of endogenous proteins that
MEKK3 but not MEKK2 is in a complex with p62 and TRAF6.
Fig. 6, B and C, shows that the MEKK3 PB1 domain and full-
length MEKK3 effectively pull down TRAF6 in a manner
requiring its interaction with the p62 PB1 domain. The inter-
action of TRAF6 and p62was unaffected bymutation of the p62
PB1 domain (data not shown). The MEKK2 PB1 domain-
MEKK3 chimera was used to demonstrate that the MEKK3-
endogenous p62-TRAF6 complex was dependent on the
MEKK3PB1domain (Fig. 6D). Replacement of theMEKK3PB1
domain with the MEKK2 PB1 domain in the MEKK3 protein
results in the loss of p62 binding and association of the chimera
in a TRAF6 complex. This chimera, however, retains its ability
to bind MEK5 (Figs. 3 and 6D).
FIGURE 4. Localization of p62 and MEKK3 in cells. A, COS7 cells were transfected with HA-MEKK3 or FLAG-p62 (wild type or K7A) individually. Expressed
MEKK3 and p62 were stained with polyclonal anti-HA (green) and anti-FLAG (M5) (red) Abs, respectively. Scale bar, 10 m. B, HA-MEKK3 (wild type or K48A) and
FLAG-p62 (wild type or K7A) were simultaneously introduced into COS7 cells and then stained as described in A. Bar, 10 m. C, lines in B indicate the sections
used for the analyses of fluorescence intensity. The relative intensity (y axis) of each fluorescence image along the line (x axis, distance in m) was calculated
as a percentage against the maximum intensity in the section. The images and section analyses shown are representative of duplicate coverslips. WT, wild type;
7K-A, K7A; 48K-A, K48A.
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MEKK3-p62 PB1 Domain Interaction Is Required for
MEKK3-TRAF6 Complexes in p62 Aggregates—Fig. 7A shows
that TRAF6 co-expressed with p62 is in p62 aggregates. Most
importantly, Fig. 7B shows that MEKK3 is also co-localized in
p62 aggregates with TRAF6. The
co-localization of MEKK3 and
TRAF6 in p62 aggregates is depen-
dent on a functional MEKK3-p62
PB1-PB1 domain interaction be-
tween the two proteins. This is
shown with the MEKK3 PB1
domain K48A mutant that disrupts
the interaction of MEKK3 with p62.
p62 Is Required for MEKK3 Acti-
vation of NF-B—Using an MEF2C
reporter gene readout for ERK5
activation shows that MEKK2 and
MEKK3 similarly activate luciferase
expression (Fig. 8A), whereas only
MEKK3 activates the NF-B
reporter gene (Fig. 8B). Lentivirus-
encoded shRNAs were used to
knock down p62 protein expression
in HEK293 cells (Fig. 8C). The level
of knockdown between five differ-
ent shRNAs targeting p62 varied
from 12 to 92% of p62 expression in
control cells. Expression of MEKK3
in control and each of the shRNA
p62 knockdown clones resulted in
similar activation of ERK5 (Fig. 8D).
The NF-B activity in the different
p62 shRNA knockdown clones cor-
related closely with the level of p62
expression, demonstrating that the
scaffold protein p62 is essential for
NF-B activation by MEKK3 (Fig.
8E). Thus, p62 is not required for
ERK5 activation in response to the
expression of MEKK3, but p62 is
required for MEKK3 activation of
NF-B.
MEKK3-p62-TRAF6 Endogenous
Protein Complex Is Regulated by
IL-1—MEKK3, p62, and TRAF6 are
in a complex measured by co-im-
munoprecipitation of the three pro-
teins, using an antibody to MEKK3
(Figs. 6A and 9A). IL-1 stimulation
of HEK293 cells resulted in a time-
dependent dissociation of MEKK3
from p62 and TRAF6 (Fig. 9A). Fig.
9B demonstrates that the dissocia-
tion of MEKK3 from p62 is a func-
tion ofMEKK3 activation. Phospha-
tase-treated MEKK3 is in an
inactive state, shown by its faster
migration on SDS-PAGE (17). In
vitro incubation of MEKK3 bound to beads with ATP activates
MEKK3 and causes an upward shift on SDS-PAGE (17). Using
inactive and activated MEKK3 in pull-down assays shows that
activation of MEKK3 resulted in decreased interaction with
FIGURE 5. Colocalization of endogenous p62 with MEKK3 but not MEKK2 in cells. A, COS7 cells were transfected
with either HA-MEKK3 (top) or -MEKK2 (bottom). Endogenous p62 and expressed MEKK3 or MEKK2 were stained
with polyclonal anti-p62 (green) and monoclonal anti-HA (red) Abs, respectively. The boxed area translucently shaded
is shown below at a higher magnification. Bar, 10 m. B, lines in A indicate the sections used for analysis. The relative
fluorescence intensity along a section line is graphically presented using the method described under “Experimental
Procedures.” The images and section analyses shown are representative of triplicate coverslips.
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both MEK5 and p62, consistent with IL-1 stimulation of cells
inducing the dissociation of the MEKK3-p62-TRAF6 complex
(Fig. 9A). Fig. 9C further shows that the association of MEKK3
andTRAF6 is dependent on p62 expression. Knockdownof p62
using shRNA inhibits coimmunoprecipitation of TRAF6 with
MEKK3. This is consistent with the findings in Fig. 7 that
MEKK3 co-localization with TRAF6 requires a functional PB1-
PB1 domain interaction between
MEKK3 and p62. Finally, shRNA
knockdown of p62 inhibits IL-1
activation ofNF-B (Fig. 9D), just as
loss of p62 inhibits MEKK3 activa-
tion of NF-B.
DISCUSSION
The significance of this work is
the discovery of a unique function
of the C-terminal region of the p62
PB1 domain. Previous characteriza-
tion of the p62 PB1 domain demon-
strated that MEK5, atypical PKCs,
and NBR1 bind to the N-terminal
basic region of p62 (2, 28, 29). p62 is
also able to homodimerize or oli-
gomerize in a PB1 domain-depen-
dent manner, which obviously re-
quires the head-to-tail binding of
the N-terminal basic region and
C-terminal acidic region of different
p62 proteins. Thus, p62 is one of
only two known proteins encoding
an A-B type PB1 domain, although
it has been suggested that atypical
PKCs may also have A-B type PB1
domains (31), butwehave not found
this interaction in our studies.4 The
other protein clearly encoding an
A-B type PB1 domain is the TRK-
fused gene (2, 32). In contrast,
MEK5 encodes an A-type PB1
domain, and MEKK2 and MEKK3
encode B-type PB1 domains.
The shRNA knockdown of p62
expression clearly inhibited MEKK3-
mediated NF-B activation. Previ-
ous reports have demonstrated that
MEKK3 regulates NF-B by regu-
lating the activity of the IKK com-
plex (19). Our findings now demon-
strate the requirement of p62 for
MEKK3 activation of NF-B, most
likely by the p62-MEKK3 complex
binding to TRAF6. The fact that
atypical PKCs and MEKK3 both
bind p62 and both have the ability to
activate NF-B suggests a redun-
dancy in p62 function that is cur-
rently not understood. The role of
MEK5binding to p62 is also unclear at the present time because
p62 is clearly not required for MEKK3-dependent activation of
ERK5. MEKK3 could bind the C-terminal region of the PB1
domain when MEK5 or atypical PKCs occupy the N-terminal
region of the p62 PB1 domain. It is likely that there is a mixture
4 K. Nakamura and G. L. Johnson, unpublished observations.
FIGURE 6. p62 PB1 domain is required for MEKK3-TRAF6 binding. A, an endogenous protein complex of
MEKK3-p62-TRAF6. Endogenous MEKK3 or MEKK2 in HEK293 cells was immunoprecipitated with anti-MEKK3
and -MEKK2 Abs, respectively. The absorbents were sequentially analyzed with anti-TRAF6, -p62, -TRAF2,
-MEKK3, and -MEKK2 Abs (left panel). The right panel shows the expression of each protein in whole cell lysates
(WCL). B, p62 PB1 domain is enough for MEKK3 binding but not involved in TRAF6 binding. The MEKK3 PB1
domain pull-down assay was carried out with either FLAG-full-length (FL) or -PB1 domain (PB1) of p62 (K7A,
D69A/E70A, or K7A and D69A/E70A) and TRAF6-coexpressing cells. The absorbents (left) and whole cell lysates
(right) were analyzed with anti-TRAF6 and -FLAG (for p62) Abs. C, a MEKK3-p62-TRAF6 complex composed
by MEKK3-p62 PB1 domain interaction. p62 (K7A or D69A/E70A) or empty vector was expressed with
HA-MEKK3 and FLAG-TRAF6. MEKK3 protein was immunoprecipitated with anti-HA Ab and separated on
an SDS-polyacrylamide gel. The absorbents (left) and whole cell lysates (right) were analyzed by anti-
TRAF6, -p62, and -HA Abs, sequentially. D, a complex composition of TRAF6 and MEKK3 through endog-
enous p62. HA-MEKK2, -MEKK3, -MEKK2PB1-MEKK3 chimera, or empty vector with FLAG-TRAF6 was
expressed in cells. HA immunoprecipitates (left) and whole cell lysates (right) were analyzed by anti-
TRAF6, -p62, -MEK5, and -HA Abs. I.P., immunoprecipitation. WT, wild type; 69.70DE-AA, D69A/E70A; 7K-A,
K7A.
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FIGURE 7. Colocalization of MEKK3 and TRAF6 in cells. A, p62-TRAF6 colocalization was shown in COS7 cells transfected with FLAG-TRAF6 together with
(lower left panel) or without (upper left panel) FLAG-p62. Expressed TRAF6 and p62 were stained with anti-TRAF6 (green) and -p62 (red) Abs, respectively. A line
in a composite image of the lower left panel indicates the section used for an analysis of fluorescence intensity. Section analysis in the right panel is conducted
using the same method as for Fig. 5. B, p62-dependent MEKK3-TRAF6 binding. FLAG-TRAF6 and HA-MEKK3 (wild type or K48A, which inhibits PB1 domain
interaction with p62) were expressed with or without wild type p62 in the indicated combinations. Localization of TRAF6 (anti-TRAF6 Ab) (green) and MEKK3
(anti-HA (12CA5) Ab) (red) was identified. Each line in the images was subjected to a section analysis of fluorescence intensity. The images and section analyses
shown in A and B are representative of duplicate coverslips. Scale bar, 10 m. WT, wild type; 48K-A, K48A.
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of p62 complexes binding atypical PKCs, MEK5, and MEKK3
for the coordinated regulation of the ERK5 and NF-B
pathways.
Previous studies have shown that MEKK3 co-immunopre-
cipitates with TRAF6 (22). Our findings indicate that this inter-
action requires p62 linking MEKK3 to TRAF6. It has also been
FIGURE 8. The effect of p62 on NF-B activation of MEKK3. A, MEF2C activation by MEKK2 and MEKK3. HA-MEKK2, -MEKK3, or empty vector at the indicated plasmid
dose (ng) with an MEF2C reporter and Renilla control reporter genes was introduced into wild type cells. After 24 h, the cells were deprived of serum for 8 h and then
lysed following a manufacturer’s instruction. MEF2C reporter activity was measured against Renilla reporter (MEF2C/Renilla) and represented as relative luciferase
activity (y axis). The data are shown as the average of all samples for each condition with S.D. (error bars). B, MEKK3 but not MEKK2 activates NF-B. An NF-B reporter
gene was substituted for the MEF2C reporter and used for the luciferase assay as in A. C, p62 knockdown performed in HEK293 cells using different lentiviral p62
shRNAs. p62 shRNA in pLKO.1 vector (five independent clones (sh#1 to 5) and one control clone (CTR)) was introduced into HEK293 cells using lentiviral infection. Stably
infected cells were selected in the presence of puromycin. The expression of p62 in each clone was assessed by anti-p62 Ab immunoblotting. The relative intensity of
p62 expression in the different clones was standardized to ERK2 expression and shown as the relative numbers. An anti-ERK2 blot was used to show equal loading in
each cell lysate (bottom). D, MEKK3 activation of ERK5 is independent of p62. HA-MEKK3 or empty vector was expressed in each of p62 knockdown and control cells.
ERK5 activation was measured by both anti-phospho-ERK5 Ab (top) and a mobility shift of ERK5 bands (middle). MEKK3 expression was monitored by anti-HA Ab
(bottom). E, MEKK3 regulation of NF-B activation requires p62 expression. The NF-B reporter assay was conducted using p62 knockdown cells. HA-MEKK3 or empty
vector at 12 ng of plasmid was transfected into each shRNA clone with NF-B and Renilla luciferase reporter constructs. 24 h after transfection, the cells were
serum-starved for 8 h and then harvested for the luciferase assay. NF-B reporter activity was measured against Renilla reporter (NF-B/Renilla). MEKK3-induced NF-B
activation was calculated as -fold increase against empty vector control (y axis). The data are shown as the average of the -fold increase  S.D. (error bars). The bottom
panel shows the levels of transfected MEKK3 using anti-HA Ab blotting.
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suggested that MEKK3 is required for tumor necrosis factor 
and IL-1 activation of NF-B (19, 22), but we do not see the
requirement of MEKK3 or p62 for activation of NF-B in
response to tumor necrosis factor .4 Rather we propose that a
major function of MEKK3 is related to its co-localization with
p62 in cytoplasmic aggregates for p62-TRAF6-dependent reg-
ulation of NF-B. This complex is clearly regulated by IL-1 for
activation of NF-B.
Interestingly, it is now recognized that autophagy is defective
and p62 is overexpressed inmany tumor cells (14, 33–35). Nor-
mally, autophagy is thought to mediate p62 elimination and to
suppress tumorigenesis. However, defective autophagy allows
overexpression of p62 that promotes tumorigenesis. The sus-
tained p62 overexpression in tumor cells with defective auto-
phagy appears to dysregulate NF-B signaling, and altered
NF-B regulation resulting from p62 overexpression is pro-
posed to be a primary mechanism for enhancing tumorigenesis
(14). Our studies presented here demonstrate that MEKK3
binds p62 and define the PB1 domain interaction properties for
the two proteins. Furthermore, we show that the MEKK3-p62
interaction can occur in cytosolic p62 aggregates or speckles
and that the MEKK3-p62 complex with TRAF6 mediates
NF-B activation. It will be interesting to determine in future
studies if MEKK3 is involved in dysregulated NF-B signaling
observed with defective autophagy and p62 overexpression in
different tumor cells. It is possible that cytokines such as IL-1
play a role in altering NF-B signaling when autophagy is dys-
regulated by p62 overexpression.
FIGURE 9. Role of the endogenous MEKK3-p62-TRAF6 complex in IL-1-induced NF-B activation. A, IL-1 stimulation induces dissociation of the MEKK3-
TRAF6 complex. HEK293 cells were treated with IL-1 (10 ng/ml) for the indicated times. After cell lysis, MEKK3 immunocomplexes were analyzed with the
immunoblotting of anti-TRAF6, -p62, and -MEKK3 Abs. The expression of each protein is shown in the right panel. B, binding of p62 to MEKK3 in vitro. MEKK3 was
immunoprecipitated from cells expressing HA-MEKK3 or empty vector with anti-HA Ab and protein G-Sepharose beads. MEKK3 on the beads was treated with
or without protein phosphatase (PP) or used for an in vitro kinase assay (IVK) with ATP for MEKK3 autophosphorylation and activation (shown by upward gel
shift of MEKK3). After extensive washing, the MEKK3-bound beads were incubated with lysates from cells expressing FLAG-MEK5 (wild type) (left) or FLAG-p62
(K7A) (right). Top, FLAG-MEK5 or -p62 in MEKK3 immunoprecipitates were analyzed with anti-FLAG Ab blotting. Middle, amount of MEKK3 on the beads. The
bottom graphs show the relative band intensities of FLAG-MEK5 and -p62 in MEKK3 immunoprecipitates. C, requirement of p62 for a MEKK3-TRAF6 complex.
MEKK3 in p62 knockdown (sh#4) or control (CTR) cells was immunoprecipitated with anti-MEKK3 Ab, and each immunoprecipitate was subjected to the
immunoblotting of anti-TRAF6, -p62, and -MEKK3 Abs (left). Expression of each protein is shown in the right panel. D, requirement of p62 for IL-1-induced NF-B
activation. The NF-B reporter assay was conducted using p62 knockdown (sh#4) and control cells. NF-B and Renilla luciferase reporter constructs were
transfected into shRNA knockdown or a control cell, HEK293 cells. 24 h after transfection, the cells in a serum-free medium were stimulated with the indicated
concentration of IL-1. After 8 h of incubation, cells were harvested, and NF-B reporter activity was measured against the Renilla reporter (NF-B/Renilla). The
data are shown as the average of the relative luciferase activity  S.D. (error bars). I.P., immunoprecipitation.
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